Phase 4
N=600
Premature Discontinuation of Contraceptive Implants
Contraception Behavior
Bottom Line
View on ClinicalTrials.gov: NCT04828824 ↗Enrolled (actual)
600
Serious AEs
0.0%
Results posted
Apr 2026
Primary outcome: Primary: Number of Participants With Implant Continuation — 219; 225 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Ethinyl Estradiol / Norgestimate Oral Tablet (Drug)
- Age
- Pediatric, Adult · 14+ yrs
- Sex
- Female
- Sponsor
- University of Colorado, Denver
- Primary completion
- Nov 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Implant Continuation |
219; 225 | — |
| SECONDARY Overall Satisfaction With Contraceptive Implant |
11; 9; 16; 16; 24; 20 | — |
Summary
To compare rates of etonogestrel implant discontinuation in implant initiators who are given advance provision of combined oral contraceptive pills (COCs) and a bleeding rescue regimen (COCR intervention) to participants given standard counseling (comparator).
Eligibility Criteria
Inclusion Criteria
- You are between ages of 14 to 22.9 years.
- Started etonogestrel implant for the first time and have never used the implant before.
Exclusion Criteria
- There is any contraindication to estrogen containing birth control.
- Desire of pregnancy in next 12 months.
- Plans to move from the area in next 12 months and is not able to come to the clinic.
Data sourced from ClinicalTrials.gov (NCT04828824). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.